Healthcare / Medical DevicesBSE
$136.95
+2.05 (+1.52%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $26.0M · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
41/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$755M
P/E
12.8x
↓EV/EBITDA
12.5x
↑ROE
12.5%
↑Gross Margin
46.6%
↓Debt/Equity
0.10
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+37.4%
FCF CAGR
—
FCF margin
9.0%
FCF / Net income
0.60x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $288.9M · net income $43.7M · FCF $26.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $288.9M | $288.9M | $332.9M | $246.0M | $111.5M |
| Net Income | $43.7M | $43.7M | $49.4M | $29.8M | $12.5M |
| EBITDA | $63.0M | $63.0M | $79.7M | $47.3M | $31.3M |
| EPS | 7.94 | 7.94 | 8.96 | 5.41 | 2.27 |
| Gross Margin | 46.6% | 46.6% | 45.8% | 43.2% | 59.9% |
| Operating Margin | 12.9% | 12.9% | 16.4% | 13.3% | 6.1% |
| Net Margin | 15.1% | 15.1% | 14.8% | 12.1% | 11.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.10 | 0.10 | 0.18 | 0.19 | 0.09 |
| Cash Flow | |||||
| Free Cash Flow | $26.0M | $26.0M | $33.4M | $-68.4M | $-89.7M |
| Returns | |||||
| ROE | 12.5% | 12.5% | 16.2% | 11.7% | 5.6% |
| Valuation | |||||
| P/E | 12.80 | 12.80 | — | — | — |
| EV/EBITDA | 12.53 | 12.53 | — | — | — |
| P/B | 2.16 | 2.16 | — | — | — |
| Growth & Yield | |||||
| Revenue Growth | -13.2% | -13.2% | 35.3% | 120.7% | — |
| EPS Growth | -11.4% | -11.4% | 65.6% | 138.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
15.2%
EPS terminal req.
$12.15
Spread vs growth
-26.6%
5Y implied EPS CAGR
13.1%
EPS terminal req.
$14.70
Spread vs growth
-24.5%
10Y implied EPS CAGR
11.5%
EPS terminal req.
$23.68
Spread vs growth
-22.9%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-15.8%
Start / end P/E
18.2x → 17.2x
EPS bridge
8.96 → 7.94
Residual
+0.6%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.